Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors

• Päätekijät: Alice Indini (Tekijä), Erika Rijavec (Tekijä), Michele Ghidini (Tekijä), Alessio Cortellini (Tekijä), Francesco Grossi (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2021-05-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS) being the most frequently mutated isoform. Historically, KRAS has been acknowledged as "undruggable",...